{
  "@context": "http://id.who.int/icd/contexts/contextForLinearizationEntity.json",
  "@id": "http://id.who.int/icd/release/11/2024-01/mms/697911710",
  "parent": [
    "http://id.who.int/icd/release/11/2024-01/mms/1946973604"
  ],
  "browserUrl": "https://icd.who.int/browse/2024-01/mms/en#697911710",
  "code": "2A81.9",
  "source": "http://id.who.int/icd/entity/697911710",
  "classKind": "category",
  "postcoordinationScale": [
    {
      "@id": "http://id.who.int/icd/release/11/2024-01/mms/697911710/postcoordinationScale/hasManifestation",
      "axisName": "http://id.who.int/icd/schema/hasManifestation",
      "requiredPostcoordination": "false",
      "allowMultipleValues": "AllowAlways",
      "scaleEntity": [
        "http://id.who.int/icd/release/11/2024-01/mms/322466810"
      ]
    }
  ],
  "title": {
    "@language": "en",
    "@value": "Primary effusion lymphoma"
  },
  "definition": {
    "@language": "en",
    "@value": "An aggressive non-Hodgkin B-cell lymphoma composed of large cells, presenting as a serous effusion without detectable tumour masses. It is universally associated with human herpes virus 8 (HHV-8)/Kaposi sarcoma herpes virus (KSHV) [HHV-8/KSHV]. It mostly occurs in the setting of immunodeficiency; most cases have been reported in HIV positive patients. The most common sites of involvement are the pleural, pericardial, and peritoneal cavities. The prognosis is extremely unfavorable."
  },
  "indexTerm": [
    {
      "label": {
        "@language": "en",
        "@value": "Primary effusion lymphoma"
      }
    },
    {
      "label": {
        "@language": "en",
        "@value": "Primary effusion lymphoma associated with the human immune deficiency virus infection"
      },
      "foundationReference": "http://id.who.int/icd/entity/945945187"
    }
  ]
}